16
Mar
2023
The Last Mile of Hepatitis C Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2023
When Life-Saving Medicines Are Ammunition in a Trade War
In early January, I held a telemedicine visit with a patient who reported a positive at-home COVID test and mild shortness of breath. During the visit, I looked through her health conditions and medications and decided that it was appropriate to prescribe Paxlovid. Later that day, she received the prescription from her local pharmacy, free of charge. Afterwards, I called... Read More
15
Dec
2022
Prescribing Cancer Drugs Off-Label is Tricky. Transparency and Standards Are Needed
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Feb
2022
For China-made drugs, Sintilimab Was the Exception, Not the Rule
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.